Phase III results move Aimmune’s peanut allergy drug closer to EU market by Anna Smith | Mar 27, 2019 | News | 0 Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance. Read More
Aimmune’s peanut allergy drug hits PhIII targets by Selina McKee | Feb 21, 2018 | News | 0 A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets. Read More
First UK patient enrolled in peanut allergy trial by Selina McKee | Jul 12, 2017 | News | 0 Children and adolescents in the UK with peanut allergy are among the first to enrol in a Europe-wide study investigating a new oral immunotherapy for the condition. Read More